Intrasense — Regulatory Filings 2017

Sep 28, 2017

Press release

Montpellier, September 28, 2017

Intrasense enriches its portfolio, addressingtohigh-potential markets

Thirteen years after creation, Intrasense (FR0011179886 - ALINS), specialist in medical imaging solutions, extends its range of offer to expand its market potential, relying on its strong technological innovation capacity.

Myrian®, basis of innovation dedicated to new market practices

As an editor of diagnosis-support software solutions, recognized by medical imaging professionals – 800 hospitals across the world - Intrasense is capitalizing on its success, repositioning its product offer and sales strategy.

To anticipate and adapt to new practices and markets – Cloud, mobility, telemedicine, artificial intelligence, biomarkers, robotic applications –, Intrasense Research & Development team has designed two brand-new solutions based on major evolutions of Myrian® technology.

Myrian® Imaging Layer designed to boost strategic partnerships

This solution targets a wide range of industrial actors, from medical equipment manufacturers to health information system publishers. Myrian® Imaging Layer allows them to benefit from high-level imaging functionalities directly integrable in their offer. It reduces development and go-to-market time.

Myrian® Studio, facilitating integration of innovation for the client

Myrian® Studio provides Myrian® technology components to academic and industry Research & Development teams which work on innovation imaging applications. These turn-key tools are designed to accelerate the development and industrialization of their solutions.

"We are taking a major step forward by repositioning our offer, valuing our technological skills on new markets that appear to be broader and with strong potential, Stéphane CHEMOUNY, Intrasense Chairman and Chief Executive Officer, says. The first feedbacks have been very positive, with already several contracts under negotiation and promising business prospects as early as 2018. "

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that makes diagnosis, decision-making and therapeutic follow-up easier and much more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries uses this unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense which has been labelled 'innovative company' by the BPI has invested more than 9 million euros in Research & Development since its creation.

For more information please visit www.intrasense.fr/.

Contacts

Intrasense Stéphane Chemouny Chairman and Chief Executive Officer Président Christophe Lamboeuf Deputy Managing Director Tel: 01 48 04 32 83 investor@intrasense.fr

NewCap Investor Relations and Financial Communication Valentine Brouchot Pierre Laurent Tel: 01 44 71 94 96 intrasense@newcap.eu